title: Can nafamostat mesilate be used for temporary management of hemodialysis in a patient with heparin-induced thrombocytopenia (HIT)?
authors.forename: T
authors.initials: T
authors.lastname: Matsuo
authors.forename: M
authors.initials: M
authors.lastname: Matsuo
authors.forename: S
authors.initials: S
authors.lastname: Ouga-Maruyama
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000627:therapeutic use*; D001550:Benzamidines; D006146:Guanidines / Q000009:adverse effects / Q000627:therapeutic use*; D006493:Heparin / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015539:Platelet Activation / Q000187:drug effects; D010979:Platelet Function Tests; D006435:Renal Dialysis; D012449:Safety; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000517:prevention & control; D013927:Thrombosis / Q000209:etiology / Q000517:prevention & control*; D014511:Uremia / Q000628:therapy
chemical_list: D000925:Anticoagulants; D001550:Benzamidines; D006146:Guanidines; D006493:Heparin; C032855:nafamostat